Skip to content

Denali Therapeutics Inc. DNLI Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax

Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax at other companies

HTF
Heartflow, Inc. Common StockHTFL
-$522K-1,438%
Denali Therapeutics Inc. logo
Denali Therapeutics Inc.DNLI
-$1.36M-8,124%
Jackson Financial logo
Jackson FinancialJXN
-$575M-190%
Summit Therapeutics logo
Summit TherapeuticsSMMT
-$176K-32.3%
Community Financial System logo
Community Financial SystemCBU
-$548.17M+14.7%
Popular logo
PopularBPOP
-$993.41M+24.7%

Other financials

Income statement

See full
Revenue-
Operating income-$137.4M+5.6%
Net income-$128.4M+3.4%
EPS (diluted)-$0.69+11.5%

Balance sheet

See full
Cash & equivalents$390.7M+551%
Total debt$40.0M-22.3%
Total equity$926.1M-17.5%
Total assets$1.3B-0.4%

Cash flow

See full
Operating cash flow-$131.2M+0.2%
CapEx$2.5M-51.4%
Free cash flow-$133.7M+2.1%

Valuation

See full
Market cap$3.93B+54.2%

Profitability

See full
Operating margin-37,938%-37,986pp
Net margin-33,121.9%-33,159pp
FCF margin-31,736.3%-31,830pp

Returns & leverage

See full
Return on equity-49.6%+34.2pp
Debt / equity0.0×
Current ratio9.3×-0.3×

Where this comes from

Reported directly by Denali Therapeutics Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax.

The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Denali Therapeutics Inc.'s other comprehensive income loss available for sale securities adjustment before reclassification adjustments net of tax.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Denali Therapeutics Inc.'s other comprehensive income loss available for sale securities adjustment before reclassification adjustments net of tax?
Denali Therapeutics Inc. (DNLI) reported other comprehensive income loss available for sale securities adjustment before reclassification adjustments net of tax of -$1.36M in Q1 2026.
How has Denali Therapeutics Inc.'s other comprehensive income loss available for sale securities adjustment before reclassification adjustments net of tax changed year-over-year?
Denali Therapeutics Inc.'s other comprehensive income loss available for sale securities adjustment before reclassification adjustments net of tax decreased by 8123.5% year-over-year, from $17K to -$1.36M.
What is the long-term trend for Denali Therapeutics Inc.'s other comprehensive income loss available for sale securities adjustment before reclassification adjustments net of tax?
Over 2 years (2021 to 2025), Denali Therapeutics Inc.'s other comprehensive income loss available for sale securities adjustment before reclassification adjustments net of tax has grown at a -23.0% compound annual growth rate (CAGR), from -$2.25M to -$1.34M.
What does other comprehensive income loss available for sale securities adjustment before reclassification adjustments net of tax mean?
This metric represents the unrealized gains or losses on available-for-sale debt or equity securities that have not yet been recognized in the income statement. It reflects changes in the fair value of investment portfolios held by the company due to market fluctuations. Monitoring this figure helps investors understand the potential volatility and hidden value within the company's treasury or investment holdings.